Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia

In recent years, one of the most successful advances in treating acute myeloid leukaemia (AML) has been the combination of the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax with hypomethylating agents (decitabine or azacytidine). This combination treatment has an accelerated approval by the Food an...

Descripción completa

Detalles Bibliográficos
Autores principales: Báez-Gutiérrez, Nerea, Rodríguez-Ramallo, Héctor, Moreno, María Antonia-Pérez, Arboli, Eduardo-Rodriguez, Abdel-kader Martín, Laila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404627/
https://www.ncbi.nlm.nih.gov/pubmed/34471510
http://dx.doi.org/10.1177/20406207211040335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404627/
https://www.ncbi.nlm.nih.gov/pubmed/34471510
http://dx.doi.org/10.1177/20406207211040335

Ejemplares similares